Literature DB >> 15643991

Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression.

George V Mazariegos1, Alan F Zahorchak, Jorge Reyes, Holly Chapman, Adriana Zeevi, Angus W Thomson.   

Abstract

Dendritic cell (DC) subsets regulate alloimmune responses and may play a role in transplant tolerance. We extend an analysis of circulating precursors (p) of CD11c(+) CD123(-/lo) (IL-3Ralpha(-/lo)) (pDC1) and CD11c(-) CD123(hi) (pDC2) DC subsets in primary cadaveric liver allograft recipients. Additionally, we examine DC subset levels in relation to the nature and extent of immunosuppressive therapy. The data consolidate the finding that the pDC2/pDC1 subset ratio is significantly higher in patients on minimal calcineurin inhibitor monotherapy undergoing successful weaning (n = 36) and in those off all anti-rejection therapy (n = 18) compared with patients on maintenance immunosuppression (n = 21). No relationship was found between the incidence of either pDC subset or the pDC subset ratio and time post-transplant or time off immunosuppression in any group. There was also no correlation between the pDC subset ratio and either prednisone or tacrolimus dose or tacrolimus trough blood level. No evidence was found that combination of these drugs influenced the incidence of pDC2 relative to pDC1. Thus, a greater prevalence of pDC2 in stable liver recipients on low dose anti-rejection therapy or in those off immunosuppression, compared with that in patients on maintenance immunosuppression, does not reflect a differential effect of anti-rejection drugs on pDC subsets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15643991     DOI: 10.1111/j.1600-6143.2004.00672.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  23 in total

Review 1.  Regulatory immune cells in transplantation.

Authors:  Kathryn J Wood; Andrew Bushell; Joanna Hester
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 2.  Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs.

Authors:  Alberto Sánchez-Fueyo; Terry B Strom
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

3.  Impairment of circulating myeloid dendritic cells in immunosuppressed liver transplant recipients.

Authors:  B M Bosma; H J Metselaar; W M W Tra; S Mancham; E J Kuipers; H W Tilanus; J Kwekkeboom
Journal:  Clin Exp Immunol       Date:  2007-07-23       Impact factor: 4.330

Review 4.  Dual protective role of HO-1 in transplanted liver grafts: a review of experimental and clinical studies.

Authors:  Chun-Feng Wang; Zhen-Yu Wang; Ji-Yu Li
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

Review 5.  Tolerogenic dendritic cells and their applications in transplantation.

Authors:  Haibin Li; Bingyi Shi
Journal:  Cell Mol Immunol       Date:  2014-08-11       Impact factor: 11.530

Review 6.  Immune monitoring post liver transplant.

Authors:  Siddharth Sood; Adam G Testro
Journal:  World J Transplant       Date:  2014-03-24

Review 7.  Organ-specific differences in achieving tolerance.

Authors:  Maria Lucia L Madariaga; Daniel Kreisel; Joren C Madsen
Journal:  Curr Opin Organ Transplant       Date:  2015-08       Impact factor: 2.640

Review 8.  Tolerogenic dendritic cells and their role in transplantation.

Authors:  Mohamed Ezzelarab; Angus W Thomson
Journal:  Semin Immunol       Date:  2011-07-07       Impact factor: 11.130

Review 9.  Tolerance signatures in transplant recipients.

Authors:  Kenneth A Newell; Laurence A Turka
Journal:  Curr Opin Organ Transplant       Date:  2015-08       Impact factor: 2.640

10.  Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents.

Authors:  Josh Levitsky; Joshua Miller; Edward Wang; Anne Rosen; Cathy Flaa; Michael Abecassis; James Mathew; Anat Tambur
Journal:  Hum Immunol       Date:  2009-01-12       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.